Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.

Chia-Te LiaoChun-Ting YangHan Siong TohWei-Ting ChangHung-Yu ChangFang-Hsiu KuoMei-Chuan LeeYi-Ming HuaHsin-Ju TangCarol StrongHuang-Tz Ou

Published in: Cardiovascular diabetology (2021)

Adding dapagliflozin to standard care is cost-effective for HFrEF in healthcare systems in the Asia-Pacific region, which supports the rational use of dapagliflozin for HFrEF in this region.

Keyphrases

healthcare
heart failure
palliative care
left ventricular
atrial fibrillation
affordable care act
health information